{"id":157106,"date":"2026-11-07T16:07:17","date_gmt":"2026-11-07T16:07:17","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/157106\/"},"modified":"2026-11-07T16:07:17","modified_gmt":"2026-11-07T16:07:17","slug":"lpa-drug-lowers-heart-risk-marker-but-not-adverse-heart-events","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/157106\/","title":{"rendered":"Lp(a) drug lowers heart risk marker but not adverse heart events"},"content":{"rendered":"<p class=\"wp-block-paragraph\">CHICAGO \u2014 Lipoprotein(a), a genetic risk factor for cardiovascular disease carried by 1 in 5 people, is the target of novel therapies trying to cut down heart attacks, strokes, and deaths in those at risk. The growing field of research aimed at the particle took a hit <a href=\"https:\/\/www.statnews.com\/2026\/09\/04\/novartis-therapy-pelacarsen-fails-cardiovascular-trial\/\" rel=\"nofollow noopener\" target=\"_blank\">earlier this year<\/a> when top-line results showed an experimental drug reduced Lp(a) but failed to lower serious outcomes.<\/p>\n<p class=\"wp-block-paragraph\">More details of the study, funded by Novartis, were revealed Saturday at the American Heart Association\u2019s scientific sessions and published simultaneously in the <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2610159\" target=\"_blank\" rel=\"noopener nofollow\">New England Journal of Medicine<\/a>.<\/p>\n<p class=\"wp-block-paragraph\">In the Phase 3 trial, the drug pelacarsen dramatically lowered Lp(a), a mashup of lipids and proteins that at high levels can heighten the risk of severe heart problems. But despite lower Lp(a), the HORIZON trial showed no difference in heart attacks, strokes, urgent coronary revascularization, or deaths in participants followed for almost five years who were randomly selected to take the drug or a placebo.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/11\/1794067637_47_stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"CHICAGO \u2014 Lipoprotein(a), a genetic risk factor for cardiovascular disease carried by 1 in 5 people, is the&hellip;\n","protected":false},"author":2,"featured_media":157107,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[9554,1288,324,8563,206,338,339],"class_list":["post-157106","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-cardiovascular-disease","tag-clinical-trials","tag-drug-development","tag-genetics","tag-novartis","tag-research","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117576024555348460","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/157106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=157106"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/157106\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/157107"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=157106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=157106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=157106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}